How to Evaluate the Cost Impact of Using Disposables in Biomanufacturing - To understand the overall cost impact of disposable technologies, it is necessary to build a robust model that covers the ent

ADVERTISEMENT

How to Evaluate the Cost Impact of Using Disposables in Biomanufacturing
To understand the overall cost impact of disposable technologies, it is necessary to build a robust model that covers the entire process.


BioPharm International
Volume 21, Issue 6

SUMMARY

I hope I have given some insight into how cost models are being used to evaluate the use of disposables technologies in biopharmaceutical manufacturing. I believe that the current focus on COGS models is underplaying the benefits of disposables technology. Typically, disposable technologies result in quicker builds of new facilities or manufacturing suites and reduced capital expenditures. The financial analysis should capture these benefits by accounting for this delay in spending (thereby reducing the project risk). The best method for accounting for these benefits is through the use of NPV analysis.

Andrew Sinclair is the managing director of Biopharm Services, Chesham, Bucks, UK, +44 1494 793 243,

REFERENCES

1. Sinclair A, Monge M. Biomanufacturing for the 21st century: Designing a concept facility based on single-use systems. Bioprocess Int. 2004 Oct supp;26–31.

2. Lim J, Sinclair A, Kim D, Gottschalk U. Economic benefits of single-use membrane chromatography in polishing: a cost of goods model. Bioprocess Int. 2007 Feb; 5(2):48–56.

3. Van Reiss R. Genentech. IBC IBC Bioeconomics Conference; 1999; Washington, DC.

4. Lim J, Sinclair A. Process economy of disposable manufacturing. Process models to minimize upfront investment. Amer Pharm Rev. 2007 Sept/Oct;10(6):114–21.

5. Sinclair A, Monge M. Concept facility based on single-use systems, part 2. Leading the way for biomanufacturing in the 21st century. BioProcess Int. 2005 Oct supp;51–55.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here